Therapeutic Targeting of Extracellular FGFR2 Activating Deletions in Intrahepatic CCA

2020 Year in Review: Cholangiocarcinoma — December 18, 2020

Extracellular domain FGFR2 in-frame deletions might be a novel genomic alteration in intrahepatic CCA with potential clinical sensitivity to FGFR inhibitors.

The activity of FGFR inhibitors in patients with CCA harboring FGFR2 fusions is well-documented; however, there is less clarity on the efficacy of FGFR inhibitors in patients with other FGFR2 activating genetic alterations. At the ASCO 2020 Gastrointestinal Cancers Symposium, the identification of a novel FGFR2 genomic alteration, namely extracellular domain FGFR2 in-frame deletions, and the oncogenic activity of FGFR inhibitors in vitro and in vivo in patients with CCA harboring this alteration were reported.

In this study, genomic alterations were assessed using the OncoPanel targeted NGS in patients with CCA before and after treatment with FGFR inhibitors in select patients. A total of 284 patients with biliary tract cancers, including 139 patients with intrahepatic CCA, underwent sequencing; the median age of the study population was 64 years (range, 20-89 years). In patients with intrahepatic CCA, genomic sequencing found IDH1 mutations in 26 patients (19%), FGFR2 fusions in 19 patients (14%), IDH2 mutations in 6 patients (4%), extracellular domain FGFR2 deletion in 5 (3.5%), BRAF V600E mutation in 4 (2.9%), and BRCA1/2 in 3 (2.2%). Of the extracellular domain FGFR2 deletions identified in intrahepatic CCA, 2 patients harbored an exon 5 deletion, FGFR2 p.H167_N173del.

Preclinical studies demonstrated the oncogenic activity of the FGFR2 p.H167_N173del extracellular domain in-frame FGFR2 deletion in in vitro and in vivo tests. In soft agar colony formation assays, the expression of the novel FGFR2 p.H167_N173del in 3T3 cells resulted in oncogenic transformation. In xenograft mouse models, 3T3 cells expressing FGFR2 p.H167_N173del formed tumors as subcutaneous xenografts.

In the clinical setting, there is preliminary evidence to suggest potential activity of FGFR2 inhibitors in patients with extracellular domain in-frame FGFR2 deletion. Two patients with metastatic intrahepatic CCA harboring FGFR2 p.H167_N173del were treated with Debio1347, an oral FGFR1-3 inhibitor. The first patient was a 65-year-old man who achieved a partial response and had been treated with the drug for 14 months. The second patient was a 48-year-old woman who achieved a partial response for 13 months and developed acquired resistance with a secondary mutation (FGFR2 p. L617F) in the kinase domain. She was subsequently treated with another FGFR inhibitor and achieved a partial response for 17 months. Following disease progression, additional genetic alterations were identified, including FGFR2 N549K and NRAS Q61K mutations.

Based on these results, extracellular domain FGFR2 in-frame deletions are a novel genomic alteration in intrahepatic CCA that may show clinical sensitivity to FGFR inhibitors, warranting further clinical testing.

Source: Cleary JM, et al. J Clin Oncol. 2020;38(suppl_4). Abstract 567.

Related Items

KEYNOTE-966: Pembrolizumab Combined With GemCis Versus GemCis Alone in Patients With BTC
2023 Year in Review: Cholangiocarcinoma
In the KEYNOTE-966 study, pembrolizumab was added to gemcitabine/cisplatin to assess outcomes in patients with advanced biliary tract cancer.
Post-hoc Analysis of the ABC-01, -02, and -03 Trials in Patients With Advanced eCCA
2023 Year in Review: Cholangiocarcinoma
This post-hoc analysis of the ABC-01, -02, and -03 clinical trials provides reference survival data for patients with advanced extrahepatic cholangiocarcinoma treated with first-line gemcitabine/cisplatin chemotherapy.
Efficacy and Safety of Tinengotinib in Patients With Advanced Refractory/Relapsed CCA Who Previously Received an FGFR Inhibitor
2023 Year in Review: Cholangiocarcinoma
Investigators pooled data from 3 trials to evaluate tinengotinib in patients with advanced, refractory/relapsed cholangiocarcinoma who previously received an FGFR inhibitor.
KLF5 Inhibition Reduces Tumor Growth and Sensitizes to Chemotherapy-Induced Cell Death in Experimental Models of CCA
2023 Year in Review: Cholangiocarcinoma
Researchers evaluated KLF5 expression and its inhibition in cholangiocarcinoma using clustered regularly interspaced short palindromic repeats technology.
Phase 2 Trial of SHR-1316 Plus IBI310 in Patients With Advanced iCCA After Inadequate Response to First-Line Therapy
2023 Year in Review: Cholangiocarcinoma
In this ongoing phase 2 study, the efficacy of SHR-1316 plus IBI310 is being evaluated in patients with advanced intrahepatic cholangiocarcinoma after inadequate response to first-line therapy.
Examination of Patients With CCA Treated With Novel Targeted Therapies After Extended Molecular Profiling on Liquid Biopsies
2023 Year in Review: Cholangiocarcinoma
Dr Mahmood presented results from the largest multi-institutional review of efficacy outcomes following targeted agents in patients with cholangiocarcinoma.
Phase 2 Component of the BEER-BTC Study: Comparing Bevacizumab Plus Erlotinib Maintenance Versus Observation in Patients With Advanced BTC
2023 Year in Review: Cholangiocarcinoma
In the phase 2 component of the phase 2/3 BEER-BTC study, bevacizumab plus erlotinib improved outcomes in patients with advanced biliary tract cancers.
The DEBATE Trial: Neoadjuvant Durvalumab Plus GemCis Versus GemCis Alone for Patients With Localized BTC
2023 Year in Review: Cholangiocarcinoma
Researchers investigated the efficacy and safety of neoadjuvant durvalumab plus gemcitabine/cisplatin (GemCis) versus GemCis alone in patients with biliary tract cancer.
The Phase 2 ADJUBIL Study of Durvalumab Plus Tremelimumab With or Without Capecitabine in BTC
2023 Year in Review: Cholangiocarcinoma
In the ongoing phase 2 ADJUBIL study, the clinical activity of immunotherapies durvalumab and tremelimumab with or without capecitabine is being assessed in patients with resectable biliary tract cancer in the adjuvant setting.
Tucatinib and Trastuzumab in Patients With Previously Treated HER2-Positive Metastatic BTC: The SGNTUC-019 Study
2023 Year in Review: Cholangiocarcinoma
This phase 2 basket study investigated the combination of tucatinib and trastuzumab as second-line treatment for patients with HER2-positive biliary tract cancer.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: